Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever: https://g.foolcdn.com/editorial/images/773219/investor-holds-glasses-while-considering-laptop.jpg
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an

2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever: https://g.foolcdn.com/editorial/images/773219/investor-holds-glasses-while-considering-laptop.jpg
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an

3 Relatively Safe Growth Stocks You Can Buy and Hold: https://g.foolcdn.com/editorial/images/773405/hands-behind-head-young-woman.jpg
3 Relatively Safe Growth Stocks You Can Buy and Hold

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

3 Relatively Safe Growth Stocks You Can Buy and Hold: https://g.foolcdn.com/editorial/images/773405/hands-behind-head-young-woman.jpg
3 Relatively Safe Growth Stocks You Can Buy and Hold

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

3 Relatively Safe Growth Stocks You Can Buy and Hold: https://g.foolcdn.com/editorial/images/773405/hands-behind-head-young-woman.jpg
3 Relatively Safe Growth Stocks You Can Buy and Hold

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

Is Vertex Pharmaceuticals Stock a Millionaire Maker?: https://g.foolcdn.com/editorial/images/772811/a-group-of-scientists-looking-at-a-report.jpg
Is Vertex Pharmaceuticals Stock a Millionaire Maker?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

Is Vertex Pharmaceuticals Stock a Millionaire Maker?: https://g.foolcdn.com/editorial/images/772811/a-group-of-scientists-looking-at-a-report.jpg
Is Vertex Pharmaceuticals Stock a Millionaire Maker?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

Is Vertex Pharmaceuticals Stock a Millionaire Maker?: https://g.foolcdn.com/editorial/images/772811/a-group-of-scientists-looking-at-a-report.jpg
Is Vertex Pharmaceuticals Stock a Millionaire Maker?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today: https://g.foolcdn.com/editorial/images/773023/getty-doubtful-expression-skeptical-not-sure-disbelieving-surprised.jpg
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today: https://g.foolcdn.com/editorial/images/773023/getty-doubtful-expression-skeptical-not-sure-disbelieving-surprised.jpg
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?: https://g.foolcdn.com/editorial/images/772621/physician-shaking-patients-hand.jpg
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?: https://g.foolcdn.com/editorial/images/772621/physician-shaking-patients-hand.jpg
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?: https://g.foolcdn.com/editorial/images/772621/physician-shaking-patients-hand.jpg
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q1 2024 Earnings CallApr 17, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Can This High-Yield Dividend Stock Keep Beating the S&P 500?: https://g.foolcdn.com/editorial/images/773104/biotech-researcher.jpg
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Can This High-Yield Dividend Stock Keep Beating the S&P 500?: https://g.foolcdn.com/editorial/images/773104/biotech-researcher.jpg
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Can This High-Yield Dividend Stock Keep Beating the S&P 500?: https://g.foolcdn.com/editorial/images/773104/biotech-researcher.jpg
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer
EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?: https://g.foolcdn.com/editorial/images/772851/investor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?

Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock: https://g.foolcdn.com/editorial/images/772774/two-investors-meet-and-discuss.jpg
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock: https://g.foolcdn.com/editorial/images/772774/two-investors-meet-and-discuss.jpg
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock: https://g.foolcdn.com/editorial/images/772774/two-investors-meet-and-discuss.jpg
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Is Pfizer Stock a Buy?: https://g.foolcdn.com/editorial/images/771826/two-investors-look-concerned-as-another-speaks.jpg
Is Pfizer Stock a Buy?

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to